RECIST 1.1 and Serum Thyroglobulin Measurements in the Evaluation of Responses to Sorafenib in Patients With Radioactive Iodine‑refractory Differentiated Thyroid Carcinoma
Oncology Letters - Greece
doi 10.3892/ol.2013.1424
Full Text
Open PDFAbstract
Available in full text
Date
June 25, 2013
Authors
Publisher
Spandidos Publications